Alemtuzumab

Results: 47



#Item
31HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. •

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. •

Add to Reading List

Source URL: www.gsksource.com

Language: English - Date: 2014-08-21 00:16:10
32Microsoft Word - Arzerra Data Backgrounder_FINAL

Microsoft Word - Arzerra Data Backgrounder_FINAL

Add to Reading List

Source URL: us.gsk.com

Language: English
334° Nordic CLL Meeting Copenhagen, September 11, 2008

4° Nordic CLL Meeting Copenhagen, September 11, 2008

Add to Reading List

Source URL: www.fda.gov

Language: English
34HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. •

HIGHLIGHTS OF PRESCRIBING INFORMATION These hig hlights do not include all the informatio n nee ded to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-09-27 15:15:31
35Fiscal Year 2012 OOPD New Awards The Office of Orphan Products Development (OOPD) is pleased to announce the new recipients of the Orphan Products Grants Program Awards for Fiscal year[removed]The recipients are as follows

Fiscal Year 2012 OOPD New Awards The Office of Orphan Products Development (OOPD) is pleased to announce the new recipients of the Orphan Products Grants Program Awards for Fiscal year[removed]The recipients are as follows

Add to Reading List

Source URL: www.fda.gov

Language: English
36CLL Support Association Registered Charity No[removed], www.cllsupport.org.uk Making sense of prognostic factors in CLL Professor Andrew Pettitt, Consultant Haematologist at the Royal Liverpool University Hospital Natural

CLL Support Association Registered Charity No[removed], www.cllsupport.org.uk Making sense of prognostic factors in CLL Professor Andrew Pettitt, Consultant Haematologist at the Royal Liverpool University Hospital Natural

Add to Reading List

Source URL: www.cllsupport.org.uk

Language: English - Date: 2013-06-19 03:40:10
379th August 2012 Dear Healthcare Provider, Availability of Mabcampath (alemtuzumab) This letter is intended to inform you that Genzyme, a Sanofi company, and its affiliates (hereinafter collectively referred to as the Com

9th August 2012 Dear Healthcare Provider, Availability of Mabcampath (alemtuzumab) This letter is intended to inform you that Genzyme, a Sanofi company, and its affiliates (hereinafter collectively referred to as the Com

Add to Reading List

Source URL: www.medicinesresources.nhs.uk

Language: English - Date: 2012-08-10 12:32:44
38

PDF Document

Add to Reading List

Source URL: www.iomsn.org

Language: English - Date: 2014-02-11 13:33:19
39PRESS RELEASE Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 Paris, France - May 30, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced tod

PRESS RELEASE Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 Paris, France - May 30, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced tod

Add to Reading List

Source URL: en.sanofi.com

Language: English - Date: 2014-05-30 02:45:11
40PRESS RELEASE European Commission Approves Genzyme’s Multiple Sclerosis

PRESS RELEASE European Commission Approves Genzyme’s Multiple Sclerosis

Add to Reading List

Source URL: en.sanofi.com

Language: English - Date: 2013-09-17 12:37:08